177 related articles for article (PubMed ID: 35209807)
21. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.
Albert JM; Kim KW; Cao C; Lu B
Mol Cancer Ther; 2006 May; 5(5):1183-9. PubMed ID: 16731750
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
25. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.
Mordant P; Loriot Y; Leteur C; Calderaro J; Bourhis J; Wislez M; Soria JC; Deutsch E
Mol Cancer Ther; 2010 Feb; 9(2):358-68. PubMed ID: 20124452
[TBL] [Abstract][Full Text] [Related]
26. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.
Ni T; Wang H; Li D; Tao L; Lv M; Jin F; Wang W; Feng J; Qian Y; Sunagawa M; Liu Y
Biomed Pharmacother; 2019 Oct; 118():109241. PubMed ID: 31351435
[TBL] [Abstract][Full Text] [Related]
27. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
28. Effect of Ag-1031 on apoptosis in gastric cancer AGS cells and its effects on the PI3K/AKT/mTOR signaling pathway.
Dai J; Liu D; Chen L; Sun L
Biotechnol Lett; 2020 Nov; 42(11):2447-2452. PubMed ID: 32651704
[TBL] [Abstract][Full Text] [Related]
29. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A
Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883
[TBL] [Abstract][Full Text] [Related]
30. Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein.
Bu T; Wang C; Jin H; Meng Q; Huo X; Sun H; Sun P; Wu J; Ma X; Liu Z; Liu K
J Cell Physiol; 2020 Apr; 235(4):3309-3319. PubMed ID: 31587272
[TBL] [Abstract][Full Text] [Related]
31. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
32. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
33. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
35. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
36. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
37. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
38. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
[TBL] [Abstract][Full Text] [Related]
40. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
Wang F; Wang Q; Zhou ZW; Yu SN; Pan ST; He ZX; Zhang X; Wang D; Yang YX; Yang T; Sun T; Li M; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():537-60. PubMed ID: 25632222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
